Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 


Print Friendly Page

Protocol No. AALL08B1

Principal Investigator DeSantes, Kenneth

Phase N/A

Age Group Both

Scope National

Sponsor Type National

Title Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Objective The purpose of the research study: to find out the specific subtype of the leukemia your child has. This study involves additional sampling and analysis that will be used as part of a research risk classification system for subjects with ALL, and this classification would be used as part of participation in other studies involving treatment. Subjects are not required to participate in this study to undergo standard care assessments of their disease or receive standard clinical treatment. This study will also involve the banking of samples for future unspecified research

Description If you agree for your child to be in this study, about 4-10 mLs (1-2 teaspoonfull) of extra bone marrow collected at the same time that it was/is collected to make the diagnosis will be collected and sent to specialized Reference Laboratories at other COG medical centers. We will send the extra bone marrow by overnight express mail to these COG Reference Laboratories where they will test them to confirm your child's diagnosis, do extra research tests, and store extra for future research. Your child will also have extra blood or bone marrow collected at times when blood and bone marrow tests are already being performed. One extra test will be on Day 8. This test will need 5 mL (1 teaspoonful) of your child's blood. Another extra test will be done after 29 days of treatment. This test will need about 2 mL or ½ teaspoonful of bone marrow. These samples will be collected when your child is already having these procedures done.

Key Eligibility
  • Newly diagnosed acute leukemia.
  • Patients must be less than 31 years of age at diagnosis.
  • Patients must not have received prior cytotoxic therapy except for steroids or intrathecal chemotherapy.
  • Patients must not have secondary ALL that developed after treatment of a prior malignancy with cytotoxic chemotherapy.

  • Applicable Disease Sites Leukemia

    Status Open

    Participating Institutions Gundersen Health System; UW Hospital and Clinics